1. Nagata Y, Hiraoka M, Shibata T et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys 2015;93:989–96.
2. Zhang J, Kong L, Jiao Q et al. Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: unsolved questions and frontiers ahead. Cancer Lett 2017;401:46–52.
3. Takayama K, Nagata Y, Negoro Y et al. Treatment planning of stereotactic radiotherapyfor solitary lungtumor.Int J RadiatOncol Biol Phys 2005;61:1565–71.
4. Matsuo Y, Shibuya K, Nagata Y et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;79:1104–11.
5. Ueki N, Matsuo Y, Togashi Y et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 2015;10:116–25.
6. Mitsuyoshi T, Matsuo Y, Shintani T et al. Pilot study of the safety and efficacy of dose escalation in stereotactic body radiotherapy for peripheral lung Tumors. Clin Lung Cancer 2018;19:e287–96.
7. Takeda A, Sanuki N, Kunieda E et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009;73:442–8.
8. Takeda A, Kunieda E, Sanuki N et al. Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Int J Radiat Oncol Biol Phys 2009;74:363–9.
9. Tsurugai Y, Takeda A, Sanuki N et al. Stereotactic body radiotherapy for patients with non-small-cell lung cancer using RapidArc delivery and a steep dose gradient: prescription of 60% isodose line of maximum dose fitting to the planning target volume. J Radiat Res 2019;60:364–70.
10. Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmile cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623–31.
11. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–54.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94: 496–509.
13. Wolbers M, Blanche P, Koller MT et al. Concordance for prognostic models with competing risks. Biostatistics 2014;15: 526–39.
14. Blanche P, Kattan MW, Gerds TA. The c-index is not proper for the evaluation of t-year predicted risks. Biostatistics 2019;20:347–57.
15. Mokhles S, Nuyttens JJME, de Mol M et al. Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making. BMC Cancer 2018;18:1–10.
16. Mokhles S, Verstegen N, Maat APWM et al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer 2015;87:283–9.
17. Zhang B, Zhu F, Ma X et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol 2014;112:250–5.
18. Matsuo Y, Chen F, Hamaji M et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. Eur J Cancer 2014;50:2932–8.
19. Chen H, Laba JM, Boldt RG et al. Stereotactic ablative radiation therapy versus surgery in early lung cancer: a metaanalysis of propensity score studies. Int J Radiat Oncol Biol Phys 2018;101:186–94.
20. Hamaji M, Chen F, Matsuo Y et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg 2015;99:1122–9.
21. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
22. Sarfati D. Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 2012;65:924–33.
23. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–51.
24. Kopek N, PaludanM, Petersen J et al. Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol 2009;93:402–7.
25. Holmes OE, MacRae R, Cook G et al. Age-not Charlson comorbidity index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer. Clin Transl Radiat Oncol 2017;5:37–41.
26. Klement RJ, Belderbos J, Grills I et al. Prediction of early death in patients with early-stage NSCLC – can we select patients without a potential benefit of SBRT as a curative treatment approach? J Thorac Oncol 2016;11:1132–9. Downloaded from https://academic.oup.com/jrr/article/62/6/1029/6382417 by guest on 29 January 2022
27. Zhang MJ, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol 2008;1:391–400.
28. Eguchi T, Bains S, Lee MC et al. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung cancer: a competing risks analysis.J Clin Oncol 2017;35:281–90.
29. Siontis GCM, Tzoulaki I, Castaldi PJ et al. External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. J Clin Epidemiol 2015;68:25–34.
論文の公開元へ
